Moreover, while BRAF V600E mutations were common, these were not associated with increased NRF2 expression in PTC, as described for other cancers [8], indicating that NRF2 pathway activation in PTC likely occurs through other mechanisms (Figure 1B). The gene discussed is BRAF; the disease is cancer.